East Idaho News on MSN5h
FDA approves weight-loss drug Zepbound for obstructive sleep apnea
The US Food and Drug Administration on Friday approved the first prescription medicine for obstructive sleep apnea: the ...
FDA approves Zepbound for obstructive sleep apnea
Zepbound, a popular weight loss drug, has become the first FDA-approved prescription medication to treat obstructive sleep ...
pharmaphorum11h
Lilly grabs first-ever FDA nod for a sleep apnoea drug
Eli Lilly's Zepbound has become the first drug to be FDA-approved for obstructive sleep apnoea (OSA), a sleep-related ...
pharmaphorum12h
Novo Nordisk sheds billions in value on obesity data
Novo Nordisk and Eli Lilly are currently a duopoly in the obesity market, which reached a value of $24 billion last year ...
Daily Journal13h
Lilly stock caught up in wave of uncertainty
Lilly investors got the jitters, saw better opportunities elsewhere, or decided to hold onto their chips. In the third ...
Tired of CPAP? FDA approval of Zepbound introduces new treatment for sleep apnea
"Zepbound is the first medication that significantly improves moderate-to-severe OSA and aids in long-term weight loss in adults with obesity." ...
3 Stocks That Could Join the Trillion-Dollar Market Cap Club Next Year
Detailed price information for Berkshire Hathaway Cl B (BRK-B-N) from The Globe and Mail including charting and trades.
Eli Lilly's Zepbound Receives FDA Approval For Obesity-Linked Sleep Apnea Drug
The FDA approved Eli Lilly's Zepbound as the first drug for obesity-linked moderate-to-severe sleep apnea, potentially transforming treatment options for 80 million Americans.